Genetically proxied inhibition of tumor necrosis factor and the risk of colorectal cancer: A drug-target mendelian randomization study

Genetically proxied inhibition of tumor necrosis factor and the risk of colorectal cancer: A drug-target mendelian randomization study

Background: Previous studies suggested that anti-TNF drugs might be repurposed as a preventive treatment for colorectal cancer. We aimed to examine whether genetically proxied inhibition of tumor necrosis factor receptor 1 (TNFR1) reduces the absolute risk of colorectal cancer through mendelian rand...

Full description

Bibliographic Details
Main Authors: Min Chen, Qian Chen, Xin-Yu Xiao, Si-Jia Feng, Xiao-Ying Wang, Tai-Chun Tang, Hui Zheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Pharmacology
Subjects:
TNF inhibition
colorectal cancer
drug target
mendelian randomization
cancer prevention
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1079953/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1079953/full

Similar Items